- Feb 2019 - Feb 2023
- Regina Rabinovich
- Página web
The world is not on track to achieve the goals proposed by WHO in the Global Technical Strategy for Malaria 2016-2030 (GTS), and currently available tools are unlikely to suffice. Vector control, our most effective strategy, is now doubly threatened by widespread insecticide resistance and residual transmission caused by mosquito behavioral adaptations that allow them to elude home-based vector control tools such as treated bed nets and indoor residual spraying.
Ivermectin is an antiparasitic drug distributed to more than 2.5 billion people over the last 30 years in mass drug administration campaigns to directly treat two Neglected Tropical Diseases (NTDs). More recently, it has been noted that ivermectin can also increase the mortality of mosquitoes that feed on treated humans or animals during a time period that can be up to 28 days, depending on the dose.
Thus, Mass Drug Administration (MDA) of ivermectin to humans and/or livestock holds potential to complement the malaria toolbox by tackling residual transmission and help the malaria community get back on track to achieve the GTS goals.
BOHEMIA will evaluate the MDA of ivermectin to humans and/or livestock in two African countries -Tanzania and Mozambique- during the malaria season, and will collect data on the epidemiological impact to support normative guidance, global and national policy change.
Should evidence be supportive, engagement with WHO and other key stakeholders will support the conditions for a policy recommendation, and subsequent national adoption.
BOHEMIA combines evidence generation and stakeholder engagement to enable the path for policy and implementation of ivermectin as a new vector control tool complementary to standard tools (treated bed nets and indoor residual spraying).
The BOHEMIAconsortium is led by ISGlobal and includes:
- Centro de Investigaçao em Saúde de Manhiça
- Ifakara Health Institute
- University Hospital Bern
- University of Oxford
- Virginia Tech
25.3 U$ million (awarded by Unitaid)
- Nelly Regina Rabinovich
- Carlos Javier Chaccour
- Mary-Ann Richardson BOHEMIA Clinical Trial Manager
- Paula Ruiz-Castillo Postdoctoral Fellow
- Júlia Montaña Lopez
- Patricia Nicolás Predoctoral Fellow
- Paulo Cunha
- Mary Mael Project Assistant
- Beatriz Fiestas Coordinadora de Comunicación
- Sonia Tomás Falco
Otros proyectosVer proyectos pasados
The Malaria Eradication Scientific Alliance - MESA is dedicated to advancing the science of malaria eradication.
Estudio de correlatos de protección frente a la malaria después de la vacunación con RTS,S/AS01E: Una evaluación inmunológica exhaustiva en el ensayo clínico de Fase III, doble ciego, aleatorizado, multicéntrico con un grupo control
Alianza Mozambiqueña para la Eliminación de la Malaria
Pregnant women as a sentinel group for malaria surveillance in an era of changing malaria transmission
A path towards new diagnostic and prevention tools for severe infectious pathologies
Exploration of the singularities of the sugar nucleotide metabolism and description of novel glycosylation pathways in the malaria parasite
Investigating new aspects of the mechanisms and biological functions of epigenetic variation in malaria parasites
Mechanistic aspects of anemia and splenomegaly caused by plasmodium vivax, a neglected human parasite
Transforming IPT for optimal pregnancy
Development of nanovectors for the targeted delivery in Anopheles mosquitoes of agents blocking transmission of Plasmodium parasites
Unravelling Disease Tolerance and Host Resistance in Afebrile 'P. falciparum' Infections: a Prospective Study in Mozambican Adults
P. falciparum genomic intelligence in Mozambique
Administración masiva y focal de fármacos antimaláricos para avanzar hacia la eliminación de la malaria en Mozambique: acelerando la implementación de programas y políticas
MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention
Equidad y Optimización del Acceso al Diagnóstico y Tratamiento de la COVID-19 en Bolivia y Paraguay